GnRH-gemcitabine conjugates for the treatment of androgen-independent prostate cancer: Pharmacokinetic enhancements combined with targeted drug delivery

Bioconjugate Chemistry

Volumn 25, Issue 4, 2014, Pages 813-823

  Karampelas, Theodoros ^a   Argyros, Orestis ^a   Sayyad, Nisar ^b   Spyridaki, Katerina ^c   Pappas, Charalampos ^b   Morgan, Kevin ^d   Kolios, George ^e   Millar, Robert P ^f,g,h   Liapakis, George ^c   Tzakos, Andreas G ^b   Fokas, Demosthenes ⁱ   Tamvakopoulos, Constantin ^a  

^a Academy of Athens Biomedical Research Foundation   (Greece)

^b Department of Chemistry Section of Organic Chemistry and Biochemistry   (United States)

^c UNIVERSITY OF CRETE   (Greece)

^d UNIVERSITY OF HULL   (United Kingdom)

^e DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

^f UNIVERSITY OF PRETORIA   (South Africa)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h UNIVERSITY OF EDINBURGH   (United Kingdom)

ⁱ UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CELL MEMBRANES; CONTROLLED DRUG DELIVERY; DISEASES; METABOLISM; SYNTHESIS (CHEMICAL); TARGETED DRUG DELIVERY; TUMORS; UROLOGY;

CELL LINES; CELL SURFACE EXPRESSION; CELL-BASED; GEMCITABINE; GONADOTROPIN-RELEASING HORMONE; HORMONE RECEPTORS; INNOVATIVE STRATEGIES; METABOLIC INACTIVATION; PROSTATE CANCERS; SOLID TUMORS;

PHARMACOKINETICS;

ANDROGEN; ANTINEOPLASTIC AGENT; GEMCITABINE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST GEMCITABINE CONJUGATE; GONADORELIN RECEPTOR; UNCLASSIFIED DRUG; DEOXYCYTIDINE; GONADORELIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL SURFACE; CONTROLLED STUDY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SYNTHESIS; HUMAN; IC 50; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PROSTATE CANCER; RECEPTOR BINDING ASSAY; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SCID MOUSE; TUMOR CELL CULTURE;

ANIMALS; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG DELIVERY SYSTEMS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; MOLECULAR STRUCTURE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, LHRH; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898994548     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc500081g     Document Type: Article

References (51)

1. Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., and Forman, D. (2011) Global cancer statistics CA Cancer J. Clin. 61, 69-90
2. Nelson, W. G., De Marzo, A. M., and Isaacs, W. B. (2003) Prostate cancer N. Engl. J. Med. 349, 366-381
3. Miyamoto, H., Messing, E. M., and Chang, C. (2004) Androgen deprivation therapy for prostate cancer: Current status and future prospects The Prostate 61, 332-353
4. Labrie, F. (1995) Endocrine therapy of prostate cancer: optimal form and timing J. Clin. Endocrinol. Metab. 80, 1066-1071
5. Limonta, P. and Manea, M. (2013) Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies Cancer Treat. Rev. 39, 647-663
6. Oudard, S. (2013) Progress in emerging therapies for advanced prostate cancer Cancer Treat. Rev. 39, 275-289
7. Millar, R. P. (2005) GnRHs and GnRH receptors Anim. Reprod. Sci. 88, 5-28
8. Millar, R. P. (2004) Gonadotropin-releasing hormone receptors Endocr. Rev. 25, 235-275
9. Sealfon, S. C. (1997) Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor Endocr. Rev. 18, 180-205
10. Payne, H. and Mason, M. (2011) Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments Br. J. Cancer 105, 1628-1634
11. Harrison, G. S., Wierman, M. E., Nett, T. M., and Glode, L. M. (2004) Gonadotropin-releasing hormone and its receptor in normal and malignant cells Endocr. Relat. Cancer 11, 725-748
12. Cheung, L. W. T. and Wong, A. S. T. (2008) Gonadotropin-releasing hormone: GnRH receptor signaling in extrapituitary tissues FEBS J. 275, 5479-5495
13. Tieva, A., Stattin, P., WikstroÌ̂m, P., Bergh, A., and Damber, J. E. (2001) Gonadotropin-releasing hormone receptor expression in the human prostate The Prostate 47, 276-284
14. Morgan, K., Stewart, A. J., Miller, N., Mullen, P., Muir, M., Dodds, M., Medda, F., Harrison, D., Langdon, S., and Millar, R. P. (2008) Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivo Cancer Res. 68, 6331-6340
15. Straub, B., MuÌ̂ller, M., Krause, H., Schrader, M., Goessl, C., Heicappell, R., and Miller, K. (2001) Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone-refractory human prostate cancers Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 7, 2340-2343
16. MezoÌ, G. and Manea, M. (2010) Receptor-mediated tumor targeting based on peptide hormones Expert Opin. Drug Delivery 7, 79-96
17. Schally, A. V. and Nagy, A. (1999) Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors Eur. J. Endocrinol. Eur. Fed. Endocr. Soc. 141, 1-14
18. Teicher, B. A. and Chari, R. V. J. (2011) Antibody conjugate therapeutics: challenges and potential Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 17, 6389-6397
19. Mullard, A. (2013) Maturing antibody-drug conjugate pipeline hits 30 Nat. Rev. Drug Discovery 12, 329-332
20. Nagy, A., Schally, A. V., Armatis, P., Szepeshazi, K., Halmos, G., Kovacs, M., Zarandi, M., Groot, K., Miyazaki, M., Jungwirth, A., and Horvath, J. (1996) Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent Proc. Natl. Acad. Sci. U. S. A. 93, 7269-7273
21. Manea, M., Leurs, U., Orbán, E., Baranyai, Z., OÌ̂hlschlaÌ̂ger, P., Marquardt, A., Schulcz, á., Tejeda, M., Kapuvári, B., ToÌvári, J., and Mezo, G. (2011) Enhanced enzymatic stability and antitumor activity of daunorubicin-GnRH-III bioconjugates modified in position 4 Bioconjugate Chem. 22, 1320-1329
22. Aggarwal, S., Ndinguri, M. W., Solipuram, R., Wakamatsu, N., Hammer, R. P., Ingram, D., and Hansel, W. (2011) [DLys(6)]-luteinizing hormone releasing hormone-curcumin conjugate inhibits pancreatic cancer cell growth in vitro and in vivo Int. J. Cancer J. Int. Cancer 129, 1611-1623
23. Sundaram, S., Durairaj, C., Kadam, R., and Kompella, U. B. (2009) Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy Mol. Cancer Ther. 8, 1655-1665
24. Engel, J., Emons, G., Pinski, J., and Schally, A. V. (2012) AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors Expert Opin. Invest. Drugs 21, 891-899
25. Miller, K., Clementi, C., Polyak, D., Eldar-Boock, A., Benayoun, L., Barshack, I., Shaked, Y., Pasut, G., and Satchi-Fainaro, R. (2013) Poly(ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases Biomaterials 34, 3795-3806
26. Carmichael, J. (1998) The role of gemcitabine in the treatment of other tumours Br. J. Cancer 78 (Suppl 3) 21-25
27. Mackey, J. R., Mani, R. S., Selner, M., Mowles, D., Young, J. D., Belt, J. A., Crawford, C. R., and Cass, C. E. (1998) Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines Cancer Res. 58, 4349-4357
28. Ueno, H., Kiyosawa, K., and Kaniwa, N. (2007) Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br. J. Cancer 97, 145-151
29. Mini, E. (2006) Cellular pharmacology of gemcitabine Ann. Oncol. 17, v7-v12
30. Moysan, E., Bastiat, G., and Benoit, J.-P. (2013) Gemcitabine versus Modified Gemcitabine: a review of several promising chemical modifications Mol. Pharmacol. 10, 430-444
31. Muenchen, H. J., Quigley, M. M., Pilat, M. J., Lehr, J. E., Brumfield, S. K., Mahoney, M., and Pienta, K. J. (2000) The study of gemcitabine in combination with other chemotherapeutic agents as an effective treatment for prostate cancer Anticancer Res. 20, 735-740
32. Buch-Hansen, T. Z., Bentzen, L., Hansen, S., Hoeyer, M., Jensen, N. V., Saxe, C., and Sengeloev, L. (2010) Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer Cancer Chemother. Pharmacol. 66, 295-301
33. Garcia, J. A., Hutson, T. E., Shepard, D., Elson, P., and Dreicer, R. (2011) Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial Cancer 117, 752-757
34. Morant, R., Bernhard, J., Maibach, R., Borner, M., Fey, M. F., ThuÌ̂rlimann, B., Jacky, E., Trinkler, F., Bauer, J., Zulian, G., Hanselmann, S., HuÌ̂rny, C., and Hering, F. (2000) Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK) Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO 11, 183-188
35. Francia, G., Shaked, Y., Hashimoto, K., Sun, J., Yin, M., Cesta, C., Xu, P., Man, S., Hackl, C., Stewart, J., Uhlik, M., Dantzig, A. H., Foster, F. S., and Kerbel, R. S. (2012) Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis Mol. Cancer Ther. 11, 680-689
36. Pulido, J., Sobczak, A. J., Balzarini, J., and Wnuk, S. F. (2014) Synthesis and cytostatic evaluation of 4- N -alkanoyl and 4- N- alkyl gemcitabine analogues J. Med. Chem. 57, 191-203
37. Pasut, G., Canal, F., Dalla Via, L., Arpicco, S., Veronese, F. M., and Schiavon, O. (2008) Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid J. Control. Release Off. J. Control. Release Soc. 127, 239-248
38. Dasari, M., Acharya, A. P., Kim, D., Lee, S., Lee, S., Rhea, J., Molinaro, R., and Murthy, N. (2013) H-Gemcitabine: a new gemcitabine prodrug for treating cancer Bioconjugate Chem. 24, 4-8
39. Maiti, S., Park, N., Han, J. H., Jeon, H. M., Lee, J. H., Bhuniya, S., Kang, C., and Kim, J. S. (2013) Gemcitabine-coumarin-biotin conjugates: a target specific theranostic anticancer prodrug J. Am. Chem. Soc. 135, 4567-4572
40. Majumdar, S. and Siahaan, T. J. (2012) Peptide-mediated targeted drug delivery Med. Res. Rev. 32, 637-658
41. Guo, Z. Z. and Gallo, J. M. (1999) Selective protection of 2â€,2â€-difluorodeoxycytidine (Gemcitabine) J. Org. Chem. 64, 8319-8322
42. Nagy, A. (2005) Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers Biol. Reprod. 73, 851-859
43. Kwon, I. K., Lee, S. C., Han, B., and Park, K. (2012) Analysis on the current status of targeted drug delivery to tumors J. Control. Release Off. J. Control. Release Soc. 164, 108-114
44. Jantscheff, P., Esser, N., Graeser, R., Ziroli, V., Kluth, J., Unger, C., and Massing, U. (2009) Liposomal gemcitabine (GemLip)-efficient drug against hormone-refractory Du145 and PC-3 prostate cancer xenografts The Prostate 69, 1151-1163
45. Kanzaki, M., Kakinuma, H., Kumazawa, T., Inoue, T., Saito, M., Narita, S., Yuasa, T., Tsuchiya, N., and Habuchi, T. (2007) Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells Oncol. Rep. 17, 761-767
46. Boven, E., Schipper, H., Erkelens, C. A., Hatty, S. A., and Pinedo, H. M. (1993) The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer Br. J. Cancer 68, 52-56
47. Frese, K. K., Neesse, A., Cook, N., Bapiro, T. E., Lolkema, M. P., Jodrell, D. I., and Tuveson, D. A. (2012) nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer Cancer Discovery 2, 260-269
48. Stathopoulos, P., Papas, S., Pappas, C., Mousis, V., Sayyad, N., Theodorou, V., Tzakos, A. G., and Tsikaris, V. (2013) Side reactions in the SPPS of Cys-containing peptides Amino Acids 44, 1357-1363
49. Laimou, D., Katsila, T., Matsoukas, J., Schally, A., Gkountelias, K., Liapakis, G., Tamvakopoulos, C., and Tselios, T. (2012) Rationally designed cyclic analogues of luteinizing hormone-releasing hormone: enhanced enzymatic stability and biological properties Eur. J. Med. Chem. 58, 237-247
50. Katsila, T., Balafas, E., Liapakis, G., Limonta, P., Montagnani Marelli, M., Gkountelias, K., Tselios, T., Kostomitsopoulos, N., Matsoukas, J., and Tamvakopoulos, C. (2010) Evaluation of a stable gonadotropin-releasing hormone analog in mice for the treatment of endocrine disorders and prostate cancer J. Pharmacol. Exp. Ther. 336, 613-623
51. Sofianos, Z. D., Katsila, T., Kostomitsopoulos, N., Balafas, V., Matsoukas, J., Tselios, T., and Tamvakopoulos, C. (2008) In vivo evaluation and in vitro metabolism of leuprolide in mice - mass spectrometry-based biomarker measurement for efficacy and toxicity J. Mass Spectrom. 43, 1381-1392